MYC and neoplasm: Another mouse model utilizing human neural stem and progenitor cells harboring transformed MYC, dominant-negative TP53, and constitutively active AKT and hTERT revealed tumor sensitivity to cyclin-dependent kinase (CDK) inhibitors, such as Palbociclib [108].